Skip to main content
Retour
Watch Compare

Silence Therapeutics plc

Qualité des données : 100%
Également cotée sous SLNCF NASDAQ
SLN
NASDAQ Manufacturing Chemicals
7,28 €
▲ 1,16 € (18,95%)
6 months return
—
Momentum
Neutral
ROE
-105,35%

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)-98,71%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-105,35%
En dessous de la moyenne du secteur (-54,47%)
ROIC-51,42%
Net Margin-15851,88%
Op. Margin-16292,84%

Sécurité

Debt / Equity
N/A
Current Ratio7,69
Interest CoverageN/A

Valorisation

PE (TTM|NTM)
-3,02 | -7,96
En dessous de la moyenne du secteur (-1,49)
P/B Ratio3,61
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -62,33 M
Capital efficient — spends only 9,84% of revenue on capex

Price History

Tendances Financières

Objectif de Cours des Analystes

5 analystes
Buy
+350.5%
upside to target
Actuel
7,28 €
Consensus Target
32,80 €
4,00 €
Bas
75,00 €
Haut
Prévisions
P/E Prévisionnel
-7,96
BPA Prévisionnel
-0,72 €
CA Est.
4,68 M

Surprises de Résultats

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -0,19 € · Rev Est: 1,55 M
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -0,60 € -0,55 € -0,15 € -0,27 € — —
Estimate -0,42 € -0,21 € -0,21 € -0,49 € -0,19 € -0,21 €
Surprise -44,58% -166,66% +27,42% +44,90% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) -98,71% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -105,35% · Net Margin: -15851,88%
Revenue (TTM) 559 000,0 Net Income (TTM) -88,61 M
ROE -105,35% ROA -56,80%
Gross Margin 61,54% Operating Margin -16292,84%
Net Margin -15851,88% Free Cash Flow (TTM) -62,33 M
ROIC -51,42% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 7,69
Debt / Equity N/A Current Ratio 7,69
Interest Coverage N/A Asset Turnover 0,00
Working Capital 116,25 M Tangible Book Value 63,45 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -3,02 · EV/EBITDA: N/A
P/E Ratio -3,02 Forward P/E -7,96
P/B Ratio 3,61 P/S Ratio 478,25
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 57,09 Fwd Earnings Yield N/A
FCF Yield -23,31%
Market Cap 267,34 M Enterprise Value 185,31 M

Per Share

EPS: -0,63 · FCF/Share: -1,32
EPS (Diluted TTM) -0,63 Revenue / Share 0,01
FCF / Share -1,32 OCF / Share -1,32
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 70,34% · CapEx/Rev: 9,84%
CapEx / Revenue 9,84% FCF Conversion 70,34%
SBC-Adj. FCF -70,40 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue 559 000,0 43,26 M
Net Income -88,61 M -45,31 M
EPS (Diluted) -0,63 -0,33
Gross Profit 344 000,0 31,45 M
Operating Income -91,08 M -63,32 M
EBITDA — —
R&D Expenses 67,75 M 67,88 M
SG&A Expenses — —
D&A — —
Interest Expense — —
Income Tax 11 000,0 845 000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 131,44 M 202,64 M
Total Liabilities 69,14 M 68,61 M
Shareholders' Equity 62,30 M 134,02 M
Total Debt — —
Cash & Equivalents 11,28 M 121,33 M
Current Assets 118,66 M 187,37 M
Current Liabilities 13,61 M 16,82 M

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)
Métrique Action Médiane du Secteur
P/E -3,0 -1,5
P/B 3,6 1,6
ROE % -105,4 -54,5
Net Margin % -15851,9 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock
BBC logo BBC Virtus Biotech Clinical Trials ETF
0,89% weight
SNTKX SNTKX
0,01% weight
SNTCX SNTCX
0,01% weight
SNTFX SNTFX
0,01% weight
SNTDX SNTDX
0,01% weight